🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — cardiovascular outcomes arm Page 3

Orforglipron ATTAIN-4 — cardiovascular outcomes arm

TrialTracker_MD Fri, Feb 27, 2026 at 7:53 AM 21 replies 544 viewsPage 3 of 5
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 27, 2026 at 12:08 PM#11

Moderator note: Great discussion, everyone. Just a reminder to keep things civil and evidence-based.

Thread quality is excellent — keep it up. 👍

40 12PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 37 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Feb 27, 2026 at 12:25 PM#12

Slightly tangential to Orforglipron ATTAIN-4 but mike_nyc reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

45 20lucas_SP_BR, lisa_labSD, adam_van and 42 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Feb 27, 2026 at 12:42 PM#13
AussieAnna said:
Follow-up question: what labs did your doctor order to monitor this

This is exactly right. AussieAnna articulated what I have been trying to explain to my friends for months. The Orforglipron ATTAIN-4 aspect is what made the difference for me.

36 17SkepticalSean, Dr.CardioMD, EndoResFellow and 33 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Feb 27, 2026 at 12:59 PM#14

Saving this for reference. Quality thread.

Last edited: Feb 27, 2026 at 1:59 PM
43 10VendorMark, COA_Karl, MikeFit_NJ and 40 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Feb 27, 2026 at 1:16 PM#15

Adding my data to this Orforglipron ATTAIN-4 discussion:

MetricBaselineMonth 4Month 6
Weight260 lbs220 lbs205 lbs
A1C6.4%6.2%5.2%
hsCRP4.03.01.0

Protocol: Tirzepatide 15mg/wk, resistance training 3x/wk, protein 1.2g/kg/day.

20 19RickReta_CO, PharmHunterJen, TomTeleRx and 17 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register